Diagnostic Substances: ImmuCell Corporation (NASDAQ:ICCC), Vermillion (NASDAQ:VRML), Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Chembio Diagnostics (NASDAQ:CEMI)

ImmuCell Corporation (NASDAQ:ICCC) today announced that Mr. Paul R. Wainman has been appointed to its Board of Directors effective March 31, 2014. ImmuCell Corporation (NASDAQ:ICCC) shares closed at $4.53 on last trade day. Company price to sales ratio in past twelve months was calculated as 2.28 and price to cash ratio as 2.44. ImmuCell Corporation (NASDAQ:ICCC) showed a negative weekly performance of -1.52%.

Vermillion, Inc. (NASDAQ:VRML) has announced it has acquired all issued and outstanding common shares in the capital of Privateco, including all its shares issued in accordance of existing warrants and options. The agreement will see Privateco shareholders receive $172.5 million in form of cash and a further $172.5 million in form of Vermillion shares. Based on a five day trading price, 2.7 million shares of vermilion will be issued in pursuant of the terms of agreement. Vermillion, Inc. (NASDAQ:VRML) shares fell -1.90% in last trading session and ended the day on $3.09. VRML return on equity ratio is recorded as -68.00% and its return on assets is -50.90%. Vermillion, Inc. (NASDAQ:VRML) yearly performance is 164.10%.

Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (BPH) which is in Phase III trials in the United States. The Company has research and development (R&D) pipeline of products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer’s disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares moved down -1.43% in last trading session and was closed at $5.51, while trading in range of $5.42 – $5.59. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) year to date (YTD) performance is -9.23%.

Chembio Diagnostics Inc (NASDAQ:CEMI) announced today that its HIV 1/2 STAT-PAK® Assay received CE Mark approval from European regulators. The Chembio HIV 1/2 STAT-PAK® Assay is now cleared for commercialization within the European Union for rapid, POC detection of HIV. Chembio Diagnostics Inc (NASDAQ:CEMI) on last trading day company shares ended up $3.43. Chembio Diagnostics Inc (NASDAQ:CEMI) distance from 50-day simple moving average (SMA50) is -2.24%. Analysts mean target price for the company is $6.00.